New York, NY, March 08, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, filed a Form N-CSR disclosing its schedule of portfolio holdings as of December 31, 2017.
In reporting its annual results for its medical device division, Daxor cited a 25% rise in kit sales related to cardiology use as well as an uptrend in overall kit sales for blood volume usage across all indications. In addition, the Company sold a new BVA-100 system to Self Regional Healthcare of Greenwood, South Carolina for use in their cardiology department following a successful pilot program.
Dr. Priya V. Kumar, a cardiologist at Self Regional was previously quoted as saying: “The BVA-100 has significantly improved our management of heart failure patients. It has proved to be a valuable tool in assessing volume status in difficult heart failure patients, especially those that are obese and those that are in renal failure. The BVA-100 has provided us with a great non-invasive way to assess a patient’s volume status accurately.”
Michael Feldschuh, CEO of Daxor stated: “Sales are rising --- driven by the combination of successful outcome studies, focused sales efforts, and our client hospitals’ pressing need for improved readmission and mortality outcomes.”
Recent developments for the company in the past six months include inclusion in industry drug trials, outcome studies by researchers at academic institutions on blood volume usage in multiple indications, as well as interest from US Government agencies to improve ICU and heart failure outcomes. Soren Thompson, VP of Business Development stated: “We are working with a growing number of researchers and partners interested in improving outcomes through the use of precision blood volume analysis. The BVA-100 is widely viewed as the gold standard in this area and we are excited about the future potential for our clinical, research, and other partnerships. We are gratified there is increasing recognition of the urgent need for accurate individualized volume assessment to improve patient care and reduce hospital costs.”
Blood volume measurement is a fundamental tool for accurate diagnosis and treatment in a variety of medical and surgical conditions, such as congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia, as well as additional conditions.
Daxor Corporation manufactures and markets the BVA-100 blood volume analyzer, which is used in conjunction with a single-use diagnostic kit. The BVA -100 is the only FDA-cleared instrument which quantifies blood volume with 98% accuracy with results available in under an hour. Over a dozen widespread medical conditions benefit from accurate volume assessment to guide therapy including heart failure and ICU use, the company has focused on sales in these areas.
Copies of the N-CSR form will be mailed to the Company’s shareholders and are filed with the SEC as well as on the Company’s website at http://www.daxor.com/wp-content/uploads/2018/03/Daxor-12-31-2017-FORM-N-CSR.pdf.